License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Jun. 11, 2021	Dec. 31, 2022	Dec. 31, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment received		$ 625,000
License and collaboration revenue		267,630	$ 344,775
Accrued expenses and other current liabilities		19,727	17,157
Deferred revenue		12,595	$ 280,225
Adimab L L C
Research And Development Arrangement Contract To Perform For Others [Line Items]
Maximum additional receivable based on achievement of research milestones		14,500
Adimab L L C | License revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Additional milestone payment accrued		2,000
License and collaboration revenue		5,400
Adimab L L C | Development Regulatory and Sales Milestone
Research And Development Arrangement Contract To Perform For Others [Line Items]
Maximum option fees receivable based on achievement of research milestones		45,800
GSK
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment received	$ 625,000
Milestone payments	$ 1,450,000
Eligible royalty payments percentage	20.00%
Accrued expenses and other current liabilities		4,700
Deferred revenue		12,600
Costs related to the cost-sharing provisions		30,800
Capitalized contract cost, net		$ 6,800
Costs related to global development plan		60.00%
Payment for license agreement reimbursement of costs incurred		$ 10,200
Related party transaction, expenses from transactions with related party		900,000
GSK | License revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
License and collaboration revenue		$ 267,600